Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Rongfeng Zhu, Dr
CONTACT
Lead
The 95th Hospital of Putian,Putian, Fujian, China
Screening \& Enrollment (-1 to 0 week): Male T2DM patients on stable metformin (≥1500 mg/d) for ≥8 weeks are screened. CAP measurement via FibroScan® confirms MASLD (≥248 dB/m). Eligible patients provide written informed consent. Baseline \& Randomization (Day 0): Comprehensive assessments include demographics, physical exam, laboratory tests (FPG, HbA1c, insulin, HOMA-IR, liver/renal function, lipids, hsCRP), serum IGF-1/IGFBP3, and FibroScan® (CAP/LSM). Patients are then randomized 1:1 to control (metformin alone) or experimental (metformin + dapagliflozin 10 mg/d) groups. Follow-up (Weeks 4 and 12): At Week 4, patients undergo physical exam, FPG, HbA1c, liver/renal function tests, adverse event recording, and adherence assessment. At Week 12, all baseline assessments are repeated, including IGF-1/IGFBP3 and FibroScan®, to evaluate changes from baseline. Data Analysis (Weeks 13-24): Data are double-entered, cleaned, and locked. Primary analysis compares ΔIGF-1 between groups using t-test/Mann-Whitney U test with ANCOVA adjustment. Secondary endpoints, correlations, and subgroup analyses are performed. All tests are two-sided with significance at P \< 0.05 using SPSS or R software.
Age
30–60
Sex
MALE
Healthy volunteers
Not accepted
